This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $636,289 to Duke University to develop a novel, targeted gene therapy approach to inhibit metastatic castration-resistant prostate cancer (mCRPC).
The key objectives are to: 1) uncover the molecular and genomic mechanisms by which the transcription factor HOXB13 drives oncogenic transcription in mCRPC, and 2) assess the therapeutic efficacy, safety, and molecular impact of a CRISPR/Cas13d-based lipid nanoparticle (LNP) system that can selectively target and knock down HOXB13 expression in visceral and bone metastases. This novel tri-targeting LNP system is designed to simultaneously target metastatic prostate cancer cells, HOXB13 transcripts, and specific organ sites like the liver, lungs, and bone.
The project includes sub-awards to the Medical College of Wisconsin to provide bioinformatics expertise, and to the Icahn School of Medicine at Mount Sinai to contribute specialized knowledge on CRISPR/Cas13d-based gene editing and nanoparticle delivery platforms. This multi-institutional collaboration aims to advance transformative gene therapy strategies to improve outcomes for patients with treatment-resistant, metastatic prostate cancer.
Generated 2/25/25, 4:02 AM